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Expression of the extracellular matrix protein tenascin in malignant and
benign ovarian tumours
KE Wilson', SP Langdon', AM Lessells2 and WR Miller'
'ICRF Medical Oncology Unit and 2Department ofPathology, Western General Hospital, Edinburgh EH4 2XU, UK.
Summary The extracellular matrix protein tenascin (TN) is overexpressed in a number of solid tumours. This,
however, is the first study to examine TN expression in ovarian tumours. TN protein was examined in frozen
sections of 50 human ovarian tumours by immunohistochemistry. Malignant and borderline tumours showed a
significantly greater incidence and intensity of stromal staining than benign tumours (P<0.0001 and P=0.038
respectively). Seven omental metastases were also examined and showed a strikingly similar protein distribution
to their primary tumour counterparts. The expression pattern of different RNA isoforms, created by alternative
splicing of the primary transcript, was identified using reverse transcription-polymerase chain reactions (RT-
PCR). The smallest TN RNA splice variant (284 bp) was found in all tumours examined, while the appearance
of larger molecular weight transcripts (-490 and 556 bp), as major forms, was predominantly limited to
malignant tumours, with 9/12 malignant tumours showing this pattern compared with 1/6 benign tumours.
These data suggest that malignant ovarian tumours have increased expression of TN compared with benign
tumours and this may be associated with induction of specific isoforms.
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Tenascin (TN) is a large hexameric glycoprotein found in the
extracellular matrix (Chiquet-Ehrismann et al., 1986;
Erickson and Bourdon, 1989). Each monomer of the
homohexamer consists of five components: a central
domain, heptad repeats, epidermal growth factor (EGF)-like
repeats, fibronectin type III repeats and a fibrinogen-like
sequence. Several different isoforms of the monomeric protein
have been identified ranging in molecular weight from 150 to
320 kDa. These isoforms are produced by alternative splicing
of the primary RNA transcript of the domain with
fibronectin type III repeats (Jones et al., 1989; Gulcher et
al., 1989). In cultured human cell lines, eight different mRNA
species, containing varying numbers of fibronectin type III
repeats, have been identified (Siri et al., 1991; Sriramarao and
Bourdon, 1993). The larger isoforms of TN are often
associated with rapidly proliferating and migrating cells
(Borsi et al., 1992).
TN is expressed transiently in developing tissues in
embryos and is absent or greatly reduced in adults. In
general, TN can be found in areas associated with cellular
proliferation and tissue reorganisation, for example, during
wound healing in human skin (Latijnhouwers et al., 1994)
and in breast tissue during gestation and lactation (Howeedy
et al., 1990). TN expression also varies in normal breast
tissue depending on the stage of the menstrual cycle
(Ferguson et al., 1990) and is overexpressed in the stroma
of breast cancer (Mackie et al., 1987) and other solid tumours
(Zagag et al., 1995; Ibrahim et al., 1993; Yamada et al., 1992;
Natali et al., 1991; Koukoulis et al., 1991; Vollmer et al.,
1990). It has been proposed that production of TN is under
paracrine control; several growth factors, including trans-
forming growth factor beta (TGF-fl), have been implicated in
regulation of TN expression (Pearson et al., 1988). Tamura et
al. (1993) examined TN expression in normal cycling human
ovaries and observed variation throughout the menstrual
cycle. Strong stromal expression of TN was only seen in
regressing corpora lutea, where tissue reorganisation was
occurring. However, expression of TN in ovarian tumours
has not previously been reported. We, therefore, report on
the expression of TN at the level of protein, by
immunohistochemistry, and RNA, by reverse transcription-
polymerase chain reaction (RT-PCR), in a series of ovarian
tumours with malignant and benign histologies.
Materials and methods
Ovarian tumours
Material was collected, at the time of initial surgery, from 50
patients presenting with ovarian tumours. Subsequent
pathological examination showed these to consist of 32
malignant, seven borderline and 11 benign. The malignant
tumours consisted of 13 serous, 12 endometrioid, three clear
cell, two mucinous carcinomas and two malignant mixed
mesodermal tumours. The seven borderline tumours con-
sisted of five mucinous and two serous. The 11 benign
tumours consisted of four fibromas, three mucinous
cystadenomas, two cystadenofibromas, one thecoma and
one mature cystic teratoma (dermoid cyst). For seven of
the malignant tumours a paired sample of omental metastasis
was available. In addition to the tumour specimens, a sample
of normal ovary, from a patient without ovarian cancer, was
included in the study for comparison. The samples were
stored in liquid nitrogen until processed for immunohisto-
chemistry and RNA extraction.
Immunohistochemistry
Frozen sections of the tumours were incubated with 20%
fetal calf serum (FCS) in Tris-buffered saline (TBS/FCS) for
10 min at room temperature. The sections were then
incubated with monoclonal mouse anti-human tenascin
antibody, diluted 1: 100 in TBS/FCS, for 30 min at room
temperature in a moist chamber. The antibody was
obtained from DAKO (High Wycombe, Bucks, UK) and
was raised against purified human TN from U251 glioma
cells. Control sections were treated with primary antibody
absorbed with excess pure TN (Gibco Life Technologies,
Paisley, UK) or simply with TBS/FCS. After washing in
TBS, sections were covered in rabbit anti-mouse biotinylated
antibody, diluted 1: 100 in TBS/FCS, followed by avidin-
biotin peroxidase complex made up in TBS; both
incubations were for 30 min at room temperature in a
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moist chamber and were followed by washing in cold TBS.
After the final wash, sections were treated with a 1 mg ml-'
solution of 3,3'-diaminobenzidine, containing 5% hydrogen
peroxide, for 5 min. The sections were counterstained lightly
in haematoxylin. Finally, the sections were dehydrated,
cleared and mounted under coverslips with DPX synthetic
mounting medium (Fisons, Loughborough, UK). All
antibodies were supplied by DAKO. Sections were exam-
ined, and distribution and intensity of staining assessed, by
two independent readers.
RNA preparation and reverse transcription
Total cellular RNA was extracted from 18 tumours (12
malignant and six benign) and the sample of normal ovary,
using Tri Reagent (Molecular Research Centre Inc. Oxford,
UK). RNA (5 ,ug) was reverse transcribed using Superscript
II reverse transcriptase (Gibco BRL) in a reaction mixture
(total volume 20,l) containing 1.875 mM magnesium
chloride, 10 mM Tris, 50 mM potassium chloride, 0.1%
Triton X-100, 0.3 mM dNTPs, 20 units RNAasin and
120 ng random hexamer to prime the reaction. Before the
addition of reverse transcriptase and RNAasin, the mixture
containing the RNA was heated to 65°C for 5 min to remove
any secondary structure. After addition of the enzyme the
sample was incubated at 42°C for 1 h. The reaction was
terminated by a 5 min incubation at 95°C.
Polymerase chain reaction
PCR was carried out using primers adapted from Siri et al.
(1992): TN1 3'-AGCTTCCAAGAAACACCACTT, TN2 5'-
GGGCAAGTAGGGTTATT. These primers are located on
the periphery of the alternatively spliced region of TN's
fibronectin type III repeats (Figure 1). Reverse-transcribed
product (equivalent to 1 jug of RNA) was added to a PCR
reaction mixture (total volume 20 pl) containing 10 pmol of
each primer, 0.3 mM dNTP and 2.5 units of Taq polymerase
(ICRF, London) in a reaction buffer containing 1.875 mM
magnesium chloride, 10 mM Tris, 50 mm potassium chloride
and 0.1% Triton X-100. PCR was carried out for 35 cycles of
93°C, 1 min; 53°C, 1 min; 72°C, 1 min. The PCR products
were run on a 1.4% agarose gel containing ethidium bromide
for 90 min at 100 V. The positions of the bands were noted
under UV light, the gel was then destained.
Specific oligonucleotide hybridisation
DNA was transferred to a nylon membrane overnight using
alkaline transfer (0.4 M sodium hydroxide). The membranes
were prehybridised for 30 min at 48°C in hybridisation
solution [5 x saline sodium citrate (SSC) containing 0.1%
sodium dodecyl sulphate (SDS), 0.1% sodium pyrophosphate,
0.05% bovine serum albumin, 0.05% polyvinyl pyrolidine,
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0.05% ficol]. The membranes were then incubated with specific
oligonucleotides, end-labelled with 732P using a DNA 5' end-
labelling system (Promega, Southampton, UK), in hybridisa-
tion solution. Oligonucleotides were designed to distinguish
the various isoforms of TN, as shown in Figure 1, (oligo 5
AGGCAGACACAAGAGCAAGC; oligo A4 TTAGC-
CGTGTCTGAGGTTGG; oligo B TGATTCCAATAG-
GTTGCTGG; oligo C GTAACGGTGGTGGATTCTGG).
Hybridisation was for 4 h at 48°C. Filters were rinsed twice
and then washed four times at 48°C for 15 min in 4 x SSC,
0.1% SDS, 0.1% sodium pyrophosphate. Autoradiography
was carried out at room temperature.
Results
TN protein expression and distribution in primary ovarian
tumours
The presence of TN was investigated by immunohistochem-
istry in 50 primary ovarian tumours (32 malignant, seven
borderline and benign) and one normal ovary. A
preliminary characterisation of the antibody showed no
cross-reactivity with fibronectin or EGF despite the
similarity of some TN domains to these molecules
(determined by an enzyme-linked immunosorbent assay,
ELISA). The antibody was then used to detect the presence
of TN by immunohistochemistry in 50 primary ovarian
tumours and one normal ovary. For all samples, a negative
control section without primary antibody showed absence of
staining. As an additional control, in a smaller number of
samples, the specificity of the antibody was verified by
addition of pure TN to the primary antibody, which totally
abolished staining.
In the section of normal ovary, the observed staining was
limited to a fine line around the smooth muscle cells of blood
vessels with negligible reaction in the surrounding ovarian
stroma (Figure 2a). TN staining was observed in 48 of the 50
tumours at variable levels (Table 1). While all staining was in
the extracellular space, the staining pattern could be classified
as either focal or diffuse. In focal staining the immunor-
eactivity was confined to structures such as blood vessels
(Figure 2b), as in the normal ovary. In sections demonstrat-
ing diffuse staining, in addition to the perivascular staining,
TN expression was observed throughout large regions of the
stroma (Figure 2c). The intensity of such staining was
arbitrarily classified as strong, moderate or weak. Hetero-
geneity was observed within sections of individual tumours
and where it was observed the score allocated was based
upon a combination of area stained and intensity of the
reaction.
The incidence and intensity of diffuse stromal staining is
shown in Tables I and II. Both the malignant and borderline
tumours showed a significantly greater incidence of diffusely
stained stroma when compared with the benign tumours
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Figure 1 Schematic diagram of the FN type III repeats of TN indicating the region of alternative splicing (filled boxes) and
showing the position of PCR primers TN1 and TN2. The PCR products previously identified by Siri et al. (1992) are shown with
their length in basepairs. The position of the oligonucleotides used to probe the PCR products is also indicated (0). Within the text
the probes are referred to as oligo 5, A4, B and C according to the FN type III repeat in which they are found.
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Figure 2 TN immunoreactivity in ovarian sections. Both normal ovary (a) and benign tumour (b) show focal staining around
blood vessels but no stromal staining. The stroma of the malignant tumour (c) shows strong staining. Sections taken from another
patient show that paired sections of primary tumour (d) and omentum (e) have a similar pattern of TN expression to each other.
The bar represents 100l m in all photographs.
(P<0.0001 and P = 0.038 respectively, by Fisher's exact test).
There was no significant difference between malignant and
borderline tumours but numbers were small. In terms of
intensity of diffuse staining, the majority of the malignant
tumours showed moderate to strong staining, while three of
four stained borderline tumours displayed only a weak
reaction. Examples of strong staining were only observed
among the malignant tumours.
No significant associations were observed between TN
expression and histology, stage or grade of malignant
tumours (data not shown), but numbers in the subgroups
were often small. Omental metastases were available from
seven of the malignant tumours; all were positive and showed
a similar pattern of staining to their counterpart primary
tumour with strong stromal staining around the nests of
tumour cells (Figure 2d).
Table I Incidence of stromal staining
Stromal staining
Negative Positive
Benign (n=I1) 10 I
Boderline (n=7) 3 4
Malignant (n=32) 6 26
Table II Intensity of stained stroma
Staining intensity
Weak Moderate Strong
Benign (n= I) 0 1 0
Boderline (n =4) 3 1 0
Malignant (n=26) 10 10 6
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TN RNA expression in primary ovarian tumours
RNA was prepared from 12 malignant tumours (five serous
and seven endometrioid) and six benign tumours (two
mucinous cystadenomas, three fibromas and one teratoma)
and was transcribed to DNA and amplified using PCR. After
electrophoresis of the PCR mixture, multiple bands could be
visualised. These included bands with apparent molecular
weights at 284, 556, 1651 and 1924 bp, corresponding to the
four products identified and sequenced by Siri et al. (1991).
In addition to these bands, other products were visible,
notably at approximately 490 bp and 750 bp. In order to
characterise the bands, the DNA was transferred to
membranes using alkaline transfer and probed with a series
of internal oligonucleotides designed to distinguish the
different isoforms. Probing with oligo S confirmed the
authenticity of the products, while the oligos A4, B and C
distinguished the PCR products by identifying which
fibronectin type III repeats they contained. As shown in
Figure 3, oligo B hybridises with all bands except the 284 bp
form, which does not contain FN type III repeat B, while
oligos A4 and C only hybridise with isoforms which contain
FN type III repeats A4 and C respectively.
Incidence of these bands varied between tumour types.
Thus, the 284 bp band appeared to be a constant feature of
all the tumour samples, while the relative proportions of the
other bands varied between tumours. We believe the
occasional appearance of double bands at the 284 bp
position is artefactual. While the intensity of bands cannot
be compared directly between tumours, because of the non-
quantitative nature of the PCR reaction, the relative intensity
of the bands within each tumour sample may be compared
across samples. Most apparent was that in 9/12 (75%)
malignant tumours there was increased intensity of the -490
and 556 bp bands, compared with the 284 bp band. In only
one out of six (17%) benign tumours were these two bands
present at relatively high intensity; in the majority of benign
tumours and the normal ovary sample these bands were
either totally absent or greatly reduced compared with the
284 bp species. The benign tumour which did contain the
-490 and 556 bp bands was the teratoma. There is a
statistically significant difference between the malignant and
benign expression patterns (75% vs 17%), giving a P-value of
0.043 by Fisher's exact test.
Discussion
These studies represent the first in which TN expression has
been observed at the level of mRNA and protein in a series
of ovarian tumours. We have been able to show differences,
in pattern of immunohistochemical staining and species of
RNA expressed, between malignant and benign tumours.
Benign tumours show a pattern of protein expression
which is similar to that seen in normal ovary, with TN
limited to focal expression around blood vessels. The
presence of TN in the walls of blood vessels in ovarian
tissue was also noted by Tamura et al. (1993). In malignant
and borderline tumours TN was also detected throughout the
tumour stroma, while malignant tumours displayed the
greatest intensity of stromal staining. These findings are
consistent with those made in other solid malignant tumours,
in which there is overexpression of TN in the stroma. These
observations on protein expression were consistent with the
presence of TN RNA. RT-PCR detected TN RNA in all
tumours examined. However, differences were seen in the pre-
mRNA splicing pattern between malignant and benign
tumours. Benign tumours showed a pattern similar to that
found in normal ovary. In malignant tissue there was
increased expression particularly of the -490 and 556 bp
products. The band observed at -490 bp had not been
previously described by Sirn et al. (1992). Further character-
isation needs to be done before we can definitively identify
this product. However, this band does hybridise with specific
a
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Figure 3 Analysis of TN RNA splicing pattern by PCR.
Products of the RT-PCR reaction were run on a 1.4% agarose
gel and stained with ethidium bromide (a). Lane I contains
normal ovary, lanes 2-4 contain benign tumour, lanes 5-9
contain malignant tumour, lane 10 is a negative control and lane
11 contains 123 bp ladder as molecular weight markers. After the
DNA was transferred to a nylon membrane the authenticity of
the bands was confirmed using oligo 5 (b), which hybridised to all
bands specifically amplified by the PCR reaction. Probing the
membrane with oligo B detected only those bands containing FN
type III repeat B and clearly shows lack of the 556 and -490bp
bands in the benign tumours (c).
internal oligonucleotides and therefore does not appear to be
an artefact of the PCR process. Furthermore, the increased
incidence of this band in malignant tumours, compared with
benign, warrants its further investigation. While PCR has not
been widely used to examine the presence of TN, our
observations are consistent with those made in other
malignant tumour types using Northern blotting, where
there is overexpression of TN, particularly of the higher
molecular weight isoforms, as compared with normal adult
tissues. These larger forms of TN may have different
functional capabilities to the forms usually expressed, owing
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to the presence of different functional units (e.g. receptor
binding sites within the FN type III repeats). It has also been
demonstrated that the expression of different isoforms of TN
is both cell cycle and pH dependent (Borsi et al., 1994, 1995).
The function of TN in vivo is not yet understood.
Notably, TN has been shown to inhibit cell adhesion to
fibronectin (Chiquet-Ehrismann et al., 1988)' and the TN
molecule has been shown to contain an anti-adhesive signal.
Further investigations have shown that TN also contains a
site that promotes cell adhesion (Spring et al., 1989). These
properties, combined with the observations that TN is
involved in the migration of cells during development of
embryonic tissues and the migration of keratinocytes in skin
wounds (Latijnhouwers et al., 1994), leads to speculation
that the overexpression of TN in tumours may be involved
in the invasion process (Riedl et al., 1995; Ishihara et al.,
1995).
In all the tumours examined, the immunoreactivity was
strongest at epithelial-mesenchymal junctions. This observa-
tion could have a number of explanations: (1) the TN may be
accumulating in the basement membrane of these regions as
would be expected with other extracellular matrix proteins;
(2) tumour cells could themselves be producing TN; or (3) the
fibroblasts in malignant tumours may be inherently different
from those in benign tumours in their capacity to express
TN. This pattern of expression is also consistent with the
hypothesis that production of TN is under paracrine control;
experimental data from model systems (Pearson et al., 1988)
showed that TGF-# can increase TN expression in chick
embryo fibroblasts, and Chiquet-Ehrismann et al. (1989)
showed that MCF-7 cells can induce production of TN in
fibroblasts via TGF-fl. Other growth factors have been
examined and found capable of inducing TN synthesis.
These include bFGF (Tucker et al., 1993), activin (Umbhauer
et al., 1992) and various combinations of cytokines (Rettig et
al., 1994). The role of growth factors, hormones and
cytokines in regulating TN production is currently being
addressed using cell lines.
In conclusion, we have demonstrated that TN may be
expressed both at the level of protein and RNA in malignant
and benign ovarian tumours. However, the malignant
tumours show increased stromal expression of TN and a
different RNA splicing pattern. The significance of these
findings warrants further investigation.
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